deferiprone has been researched along with Hepatitis C, Chronic in 2 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
Hepatitis C, Chronic: INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although IFN therapy is known to cause neutropenia, data on the risk of deferiprone (DFP)-induced haematological complications in patients receiving IFN are lacking." | 7.76 | The impact of previous or concomitant IFN therapy on deferiprone-induced agranulocytosis and neutropenia: a retrospective study. ( Ammirabile, M; Cinque, P; Costantini, S; Di Costanzo, G; Di Matola, T; Lanza, AG; Pagano, L; Prossomariti, L; Ricchi, P; Spasiano, A, 2010) |
| "Deferiprone (L1) was found to have greater efficacy at depleting myocardial iron than desferrioxamine (DFX)." | 5.32 | Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. ( Chang, JS; Peng, CT; Tsai, CH; Wu, KH, 2004) |
| "Although IFN therapy is known to cause neutropenia, data on the risk of deferiprone (DFP)-induced haematological complications in patients receiving IFN are lacking." | 3.76 | The impact of previous or concomitant IFN therapy on deferiprone-induced agranulocytosis and neutropenia: a retrospective study. ( Ammirabile, M; Cinque, P; Costantini, S; Di Costanzo, G; Di Matola, T; Lanza, AG; Pagano, L; Prossomariti, L; Ricchi, P; Spasiano, A, 2010) |
| "Deferiprone (L1) was found to have greater efficacy at depleting myocardial iron than desferrioxamine (DFX)." | 1.32 | Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. ( Chang, JS; Peng, CT; Tsai, CH; Wu, KH, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ricchi, P | 1 |
| Ammirabile, M | 1 |
| Costantini, S | 1 |
| Cinque, P | 1 |
| Lanza, AG | 1 |
| Spasiano, A | 1 |
| Di Matola, T | 1 |
| Di Costanzo, G | 1 |
| Pagano, L | 1 |
| Prossomariti, L | 1 |
| Wu, KH | 1 |
| Chang, JS | 1 |
| Tsai, CH | 1 |
| Peng, CT | 1 |
2 other studies available for deferiprone and Hepatitis C, Chronic
| Article | Year |
|---|---|
The impact of previous or concomitant IFN therapy on deferiprone-induced agranulocytosis and neutropenia: a retrospective study.
Topics: Adult; Agranulocytosis; Antiviral Agents; beta-Thalassemia; Deferiprone; Deferoxamine; Drug Therapy, | 2010 |
Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major.
Topics: Adult; beta-Thalassemia; Cardiovascular Agents; Deferiprone; Deferoxamine; Diabetes Complications; D | 2004 |